Invivyd, Inc.

Invivyd, Inc.

IVVD·NASDAQ

$1.14

+1.5%
HealthcareBiotechnology

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$151.31M
EPS-0.3000
P/E Ratio-8.10
Earnings Date08/13/2026

ivvd

Account Payables

Last Annual Value

13.74M

3-Year CAGR

108%

5-Year CAGR

11%

10-Year CAGR

5%

Invivyd, Inc.

Invivyd, Inc. Competitors Analysis of Account Payables

IVVD · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
13.74M
20.0%18.9%N/A 
OABI logo
OmniAb, Inc.
NASDAQ:OABI
1.88M
-24.8%-8.5%N/A
2.95M
-19.4%6.6%N/A
2.21M
-11.3%4.4%-4.3%
10.88M
40.8%-1.9%N/A
0.00
N/AN/AN/A
5.13M
84.6%27.1%N/A
14.44M
-1.8%8.1%18.8%
7.11M
34.0%67.6%N/A
858.00K
-16.0%-28.2%N/A
2.54M
38.7%7.0%19.7%
Invivyd, Inc.

Invivyd, Inc. Fair Value Envelope

IVVD · NASDAQ

Our analysis suggests that IVVD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.14, this represents a potential HIDDEN relative to our calculated worth for Invivyd, Inc..

Intrinsic Value
Current Price: $1.14